Cyclophilin F, also known as Cyclophilin D (CypD), is a mitochondrial member of the immunophilin family, encoded by the *PPIF* gene. It plays a critical role in regulating the mitochondrial permeability transition pore (mPTP), a key mediator of cell death pathways. CypD interacts with components of the mPTP, facilitating its opening under stress conditions such as calcium overload or oxidative stress, which can lead to loss of mitochondrial membrane potential, ATP depletion, and apoptosis. Dysregulation of CypD activity is implicated in various pathologies, including ischemia-reperfusion injury, neurodegenerative diseases (e.g., Alzheimer’s and Parkinson’s), and cancer.
Antibodies targeting Cyclophilin F/CypD are essential tools for studying its expression, localization, and function in both physiological and disease contexts. These antibodies enable detection of CypD in techniques like Western blotting, immunohistochemistry, and immunofluorescence, aiding research into mitochondrial dysfunction mechanisms. Additionally, they are used to evaluate the efficacy of therapeutic agents targeting mPTP inhibition, such as cyclosporine A derivatives, which block CypD’s peptidyl-prolyl isomerase activity. Reliable CypD antibodies are crucial for advancing understanding of mitochondrial-mediated cell death and developing treatments for related disorders. Validation in specific experimental models ensures their specificity and applicability across diverse research applications.